Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, neurodegenerative disease characterized by the loss of motor neurons. Motor neuron degeneration is probably both a cell autonomous and a nonautonomous event. Therefore, manipulating the diseased microenvironment via non-neural cell replacement could be a therapeutic strategy. We investigated a cell therapy approach using intravascular injection to transplant a specific population of c-kit 1 stem/progenitor cells from bone marrow into the SOD1G93A mouse model of ALS. Transplanted cells engrafted within the host spinal cord. Cell transplantation significantly prolonged disease duration and lifespan in superoxide dismutase 1 mice, promoted the survival of motor neurons and improved neuromuscular function. Neuroprotection was mediated by multiple effects, in particular by the expression of primary astrocyte glutamate transporter GLT1 and by the non-mutant genome. These findings suggest that this type of somatic cell transplantation strategy merits further investigation as a possible effective therapy for ALS and other neurodegenerative diseases.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a form of motor neuron disease characterized by clinical and pathological features of upper and lower motor neuron degeneration, with death from respiratory failure usually occurring within 3 -5 years from the onset of symptoms (1) . The vast majority of cases are sporadic, but 10% are familial ALS (FALS). Of these, 20% are linked to mutations in the superoxide dismutase 1 (SOD1) gene (2, 3) . A smaller number of familial and apparently sporadic cases are caused by mutations in various other genes, including ANG encoding angiogenin (4), transactive response DNA-binding Protein-43 (TARDBP) encoding for TDP-43 (5), FUS encoding fused in sarcoma (6) and very recently the optineurin gene (7) . In most FALS cases, the causative gene is still unknown (3) .Ubiquitous expression of mutant SOD1 in rodents (mice and rats) leads to a progressive selective degeneration of motor neurons with many features similar to the human disease (8, 9) . Although several hypotheses have been proposed for the mechanisms through which mutant SOD1 induces motor neuron death (i.e. excitotoxicity, oxidative damage, formation of protein aggregates, axonal transport disruption and mitochondrial dysfunction), the exact mechanisms responsible for motor neuron degeneration remain unknown (3) . Despite the relative selectivity of motor neuron cell death, several lines of evidence support the involvement of non-neuronal cells in motor neuron pathology (10) . In human and rodent ALS, loss of motor neurons is associated with the evident activation of microglia and astrocytes (11) , and dysfunction of the primary astrocyte glutamate transporter GLT1 (human EAAT2) has been observed (12) . Some of the first experimental evidence for the non-cell-autonomous nature of ALS pathogenesis came from chimeric animals containing a mixture of mutated and normal human SOD1 (13) . Further confirmation was provided by conditional deletion experiments, demonstrating that diminished mutant SOD1 levels within either microglia or astrocytes significantly modify disease progression (14, 15) .
Bone marrow-derived cell transplants in which the microglia were replaced with wild-type (wt) cells also ameliorated the disease in mice (16, 17) , although some experiments showed negative results (18) .
In agreement with in vivo observations, both human and mouse cocultures of mutant SOD1-expressing astrocytes and motor neurons have demonstrated that mutant astrocytes affect motor neuron survival (19) (20) (21) (22) . However, the relevance of these findings in human SOD1-ALS and non-SOD1 -ALS remains to be established, as the data have been obtained in high copy SOD1 models and cell culture systems that do not fully mimic the glial -motor neuronal interactions occurring in situ in the spinal cord. Notably, recent detailed characterization of SOD1 -ALS models points to cell autonomous mechanisms as the prime pathogenic event (23) . In addition, there is evidence that expression of mutant SOD1 solely in neurons is sufficient to cause disease (24) . Therefore, it is likely that both cell autonomous and non-autonomous mechanisms act in ALS pathogenesis. Manipulating the diseased microenvironment via non-neural cell replacement can be a way to modify these events. Thus, we hypothesized that the transplantation of somatic cells, to replace or enrich the spinal cord cell pool with healthy cells, might be a potential therapeutic approach for ALS. We wanted to overcome the limits of cell therapy, based on direct injection into the spinal cord, by using a cell population that is able to migrate into the central nervous system (CNS) from the blood stream. On the basis of the data in literature, some cell fractions contained in the whole bone marrow can complete this journey, but their precise identity, apart from microglia precursors, is not precisely defined (16, 17) . The bone marrow is composed of several stem and progenitor populations, including hematopoietic stem cells, mesenchymal stem cells and vascular precursors. Isolation by cell surface marker is a strategy to separate specific cell fractions (25) . C-kit is a tyrosine-kinase receptor, originally detected in a class of hematopoietic stem cells; it is also expressed in several stem cell populations including hemangioblasts (26) (27) (28) , primitive stem cells at the early embryoid stages of development and several populations of stem cells in the adult liver, brain, pancreas and heart (29, 30) . On the basis of this premise, we investigated the biological features of a Lin-c-kit + cell population derived from bone marrow to evaluate whether the cells can migrate from the blood stream into the CNS of SOD1 mice, possibly providing neuroprotective and therapeutic effects on ALS disease, as well as gaining insight into the potential mechanisms underlying the benefits provided by this cellular therapy.
RESULTS

Isolation and phenotype of a Lin-c-kit
1 population derived from bone marrow
We used immunomagnetic separation to select cells from murine bone marrow that do not express hematopoietic lineage markers [CD5, CD45R (B220), CD11b, Gr-1 (Ly-6G/C), 7-4 and Ter-119]. The cells were plated in culture and expanded for 3 -4 weeks. Adherent cells developed and were then positively selected immunomagnetically according to c-kit expression (Fig. 1A) . These cells can be grown in vitro as an adherent monolayer of homogenous c-kit + cells for at least 20 passages (Fig. 1B-D) . We selected Lin-c-kit + cells from wt and transgenic mice that ubiquitously express the green fluorescent protein (GFP) reporter gene under the control of the b-actin promoter (Fig. 1E -G) . Immunocytochemical and fluorescence activated cell sorting (FACS) profiling revealed that these cells express c-kit at high levels (.90%; Fig. 1B-D) , although they do not express hematopoietic, mesenchymal or endothelial markers (CD34, CD45, Sca-1, CD31, CD44, CD105, Thy1.1; Fig. 1H ). A fraction of these cells expressed CD13 (25 + 3.5%; Fig. 1H ). These cells were also negative for the perivascular/pericyte markers desmin and smooth muscle actin, although they expressed Oct-4 at a high level (Fig. 1F-G) . The cells expressed some pluripotency factors (Oct4, Klf4, low level of c-myc), but they were negative for Sox2, as demonstrated by western blot analysis (Fig. 1I ). c-kit + cells were positive for the astrocyte glutamate transporter protein GLT1, as demonstrated by immunocytochemistry and by western blot (Supplementary Material, Fig. S1 ).
Intravascularly transplanted c-kit
1 cells engraft in SOD1G93A mice
To assess the potential of c-kit as a tool for cell-mediated therapy, we evaluated whether c-kit + cells can reach the CNS of SOD1 mice, the animal model of ALS, after intravascular systemic injection. c-kit + cells (1 × 10 6 cells) were delivered by intravascular injection through the tail vein in SOD1 mice at 70 days of age (Fig. 2) . In order to trace the transplanted cells, we used c-kit + cells expressing GFP. To assess donor cell distribution and engraftment, the brain, spinal cord and visceral tissues were collected at the end stage of the disease. Visualization of c-kit
+ cells in the spinal cord revealed cells in isolation and in clusters ( Fig. 2B-E) . c-kit + donor cells were located in both gray and white matter regions of the spinal cord in mice with endstage disease. GFP + donor cells were specifically detected in the anterior horns, the site of active degeneration. In fact, the majority of c-kit + GFP + engrafted cells (71.3 + 6.2%) are located ventrally to a line drawn through the central canal perpendicular to the ventral spinal cord sulcus (Supplementary Material, Fig. 2A Fig. 2C and D) . Quantitative measurements of donor-derived cells in the spinal cord showed that 10 604.79 + 410.43 were present in the spinal cord, with a significantly higher concentration in the cervical and lumbar tracts than in the thoracic zone (Fig. 2I) . These values are the product of three variables: cellular engraftment, death and proliferation. Some c-kit + cells (4.18 + 0.64%) expressed the cell cycle-associated antigen Ki67, while the vast majority of cells were negative. These data suggest that transplanted cells are able to proliferate in the host tissue, but only a few divide in vivo (in particular in the cervical and lumbar enlargements) ( Fig. 2I and J) .
In vivo transplanted cells were small and appeared to maintain the in vitro phenotype (c-kit + ). They also continued to express the astrocyte glutamate transporter protein GLT1 (Fig. 3) , but did not express hematopoietic (CD45, CD11b, CD14), endothelial (CD31, VEGFR-2 + , von Willebrand factor) or pericytic antigens (desmin, a-smooth muscle actin) (data not shown). No transplanted cells showed unexpected phenotypes such as neurons or glia, and they were negative for neuroectodermal markers like GFAP (Fig. 3) . No damage, including tumor formation and inflammation, was detected in the spinal cord after implantation. No instances of GFP + transplanted cells colabeled with human SOD1 were observed in diseased animals, indicating that the transplanted GFP + cells did not fuse with host cells (Supplementary Material, Fig. S3 ). To determine whether transplanted cells present pathological changes similar to those displayed by host cells in response to disease, we examined the presence of ubiquitinated aggregates and the loss of GLT1 expression (31) . We found ubiquitin deposits in host motor neurons and astrocytes of the spinal cord (data not shown). In contrast, confocal microscopy revealed that the vast majority of transplanted donor-derived cells did not present ubiquitin aggregates upon end-stage examination ( Fig. 3G-I ). Furthermore, these cells continued to express GLT1 at the end stage of the disease (Fig. 3J -L) .
Cell transplantation delayed disease and extended survival
We first evaluated whether systemic delivery of transplanted cells could ameliorate the phenotype and extend survival in SOD1G93A mice. For the phenotypic assessment, mice were weighed weekly and the weight curve of each mouse was used to establish earliest disease onset (determined retrospectively by maximal weight before denervation-mediated muscle atrophy) as well as to identify the early symptomatic stage of disease, defined by 10% weight loss [ (14); Fig. 4A and B]. Survival was recorded (Fig. 4C) . 
Transplantation of c-kit
+ cells into SOD1G93A mice significantly extended survival by 16-17 days compared with vehicletreated (n ¼ 24) and fibroblast-injected animals (vehicle, 143 + 7 days mean survival; fibroblasts, 144 + 8 days; c-kit, 159 + 8 days; x 2 ¼ 36.46, P , 0.00001 for c-kit versus vehicle; x 2 ¼ 30.04, P , 0.00001 for c-kit versus fibroblasts; Fig. 4C ).
Extended survival resulted from delayed onset of the early symptomatic disease stage and a slower progression of later disease. c-kit + cell transplantation was observed to have a significant effect on disease onset (vehicle, 98 + 3; fibroblasts 97 + 4; c-kit: 102 + 5; vehicle versus c-kit P ¼ 0.000225; fibroblasts versus c-kit: P ¼ 0.0000754) (Fig. 4A) . Progression from onset to early disease was clearly delayed in all mice (vehicle, 132 + 5; fibroblasts 133 + 4; c-kit: 140 + 6; vehicle versus c-kit: P ¼ 0.0000079; fibroblasts versus c-kit: P ¼ 0.0000273). There was also a slowing of later disease progression, with a mean extension of 5 days (Fig. 4B) .
Neuromuscular function was also assessed in transplanted (n ¼ 24) and untreated (n ¼ 24) animals using the rotarod test. Between 16 and 19 weeks, the treated animals presented a significant improvement compared with untreated (P , 0.00001) and fibroblast-treated animals (P , 0.00001) (Fig. 4D) .
To determine whether c-kit transplantation provides protection against loss of motor neurons, we quantified the number of motor neurons in spinal cord sections and ventral spinal nerve roots.
At Day 110 of life, motor neuron loss was significantly reduced by c-kit transplantation. Mice transplanted with c-kit had 50% more motor neurons than vehicle-treated SOD1-G93A mice and fibroblast-transplanted mice (P , 0.00001); this probably accounted for the observed functional improvement (Fig. 4E) . Transplanted animals also presented with a preservation of axonal density in the L4 ventral root, while control mice showed a substantial reduction in axons. Quantitative assessment revealed that almost half of the L4 motor axons were lost in control mice (P , 0.00001), whereas in transplanted SOD1-G93A mice this loss was significantly reduced (treated versus untreated P , 0.00001), resulting in the preservation of over 75% of the axons in adult L4 ventral nerve roots (Fig. 4F ).
Mutant SOD1 abrogates the therapeutic effect of c-kit
We sought to define how mutant SOD1 G93A (mSOD1) affects the therapeutic properties of the c-kit + population after systemic transplantation into SOD1G93A mice. We generated c-kit + cells from SOD1G93A mice as described above for wt cells. These cells were genetically modified to express the reporter gene GFP. We then transplanted the mSOD1-c-kit + cells into SOD1G93A (n ¼ 24) intravenously, using the same approach used for all other transplant groups. mSOD1-c-kit 
C-kit cell transplantation induces partial preservation of spinal cord GLT1 levels
Previous studies have shown reduced levels of the mainly astroglial glutamate transporter GLT1 (hEAAT2) in ALS CNS; this reduction might play a role in disease progression (32) . The benefits of cell transplantation might derive from preservation of GLT1 levels via the prevention of host cell loss. It has been previously described that focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease due to maintenance of GLT1 expression (31) . We demonstrated that in the host spinal cord, grafted c-kit To further evaluate the role of therapeutic GLT1 expression by c-kit + cells, we knocked down (kd) GLT1, using five different GLT1 short hairpin RNAs (shRNAs) (Sigma, MISSION shRNA), with scrambled-sequence shRNA as a control. GLT1 -kd-c-kit + cells (derived using shRNA clone 7C) were expanded and further tested using immunohistochemistry and western blot. The results revealed a ≈70% reduction in These results suggest that graft-derived GLT1 preserves GLT1 levels in the spinal cord after transplantation. Taken together, these results provide at least one potential mechanism for the benefits of c-kit + cell transplantation, although other pathways may also exert effects.
Changes in growth factor levels and reduction of microgliosis after cell transplantation
The transplanted c-kit + cells may also have exerted therapeutic benefits through mechanisms other than the increased GLT1 levels. It has been previously described that c-kit + cells from the bone marrow may contribute to tissue repair (in the myocardium, for instance) by producing angiogenic cytokines such as vascular endothelial growth factor (VEGF) and angiopoietin 1-2 (33) .
To investigate whether c-kit + cells could have produced trophic factors in our experiments, resulting in neuroprotection, we conducted enzyme-linked immunosorbent assays (ELISAs) of VEGF and angiopoietin 2 (Ang 2). We found that in vitro, c-kit + cells secreted substantial amounts of VEGF and Ang 2; levels of these growth factors were higher than those in fibroblasts (P , 0.00001; Fig. 5D and E). Mutant SOD1 (mSOD1) c-kit + cells released less VEGF and Ang 2 than do untreated wt c-kit cells (wt c-kit + versus m-c-kit + : VEGF P , 0.001; Ang 2 P , 0.01). In lumbar spinal cord parenchyma transplanted with c-kit, we observed significant differences between treated and untreated groups in levels of VEGF and Ang 2 (P , 0.00001; Fig. 5F and G). Furthermore, transplantation of c-kit + mSOD1 cells into SOD1 mouse spinal cords resulted in reduced levels of VEGF and Ang 2 in comparison with the transplantation of c-kit + wt cells (wt c-kit + versus m-c-kit + : VEGF, P , 0.001; Ang 2, P , 0.01). The beneficial effect of VEGF on disease outcome in mutant SOD1-expressing rodents has been shown previously (34) . Ang 2 may also exert a neuroprotective effect (35) .
Given that these factors are key regulators of blood -brain barrier (BBB) stability (36), they may have an impact on vascular changes that have been previously described in SOD1 animals (37) . Since reduced levels of tight junction proteins that regulate the BBB have been described in SOD1 mice, we performed western blot analysis to evaluate the levels of ZO-1 and occludin. We did not observe a significant reduction of these proteins in treated or untreated SOD1G93A mice at 110 days of age (Fig. 5H) .
Next, we evaluated whether there was a change in the inflammatory response after c-kit transplantation by analyzing the microglial marker Iba1 in spinal cords of c-kit-transplanted mice compared with controls (Supplementary Material, Fig. S7 ). Immunohistochemistry revealed that compared with wt spinal cords (n ¼ 6), there was a significantly elevated microglial response in the ventral gray matter of the vehicletreated control (n ¼ 6), fibroblast-treated control (n ¼ 6) and c-kit-transplanted (n ¼ 6) SOD1G93A mice. However, the response was significantly reduced in c-kit-transplanted mice (wt, 40.2 + 3.9 units; vehicle: 106 + 6.5; fibroblast cells, 113 + 4.5; c-kit, 89.5 + 5.9; c-kit versus vehicle P ¼ 0.00101; c-kit versus fibroblasts P ¼ 0.000154). Since the reduction of levels of mutant SOD1 in microglia has been demonstrated to slow disease progression (14) , the effects of c-kit transplantation on disease progression after symptomatic onset in this study may be attributed in part to a modification of the microglial response in the spinal cord.
Coculture with c-kit 1 cells increases SOD1 -G93A motor neuron survival in cell death assays, with increased extracellular glutamate A glutamate transport defect can be mimicked in organotypic spinal cord cultures by chronic blockade of glutamate transport with the non-specific transporter inhibitor threo-bhydroxyaspartate (THA) or DL-threo-b-benzyloxyaspartate (TBOA), which raises extracellular glutamate concentrations and leads to the death of motor neurons (38) .
To determine whether c-kit cells could exert a neuroprotective effect, we performed a coculture of c-kit + cells and organotypic spinal cord cultures. Organotypic cultures were derived from lumbar spinal cords of 8-to 9-day-old rodent SOD1 and wt pups (38) . No exogenous cells were added for the first 7 days after culture preparation. Then, 1 × 10 5 cells were added and, after 7 more days, THA or TBOA was administered at a concentration of 100 mM to induce the chronic death of motor neurons. After 2-4 weeks, motor neuronspecific neurofilament immunostaining (SMI32) was used to identify and count neurons within the cultures. As shown in Figure 6 Glt1 activity is increased by co-culturing astrocytes with c-kit 1 cells and correlates with the reduction in astrocyte reactive oxygen species production
We evaluated the SOD1 -astrocytes' GLT1 activity in coculture with wt cells, mSOD1 cells, GLT1 -kd-c-kit cells or vehicle. The coculture of wt c-kit cells significantly increased the Glutamate uptake with respect to vehicle (P , 0.001), whereas the mSOD1 and GLT1-kd-c-kit cells showed a reduced effect (wt-c-kit + versus m-SOD1 P , 0.05; wt-c-kit + versus GLT1 -kd-c-kit cells; P , 0.01) (Supplementary Material, Fig. S8 ). It has been previously reported that reactive oxygen species (ROS) can also render GLT1 ineffective (39) , and one of the toxic features of mutant SOD1 astrocytes involves the production of ROS (22, 39) . Here, we observed an increase in the number of cultured SOD1 G93A astrocytes that produce ROS (Supplementary Material,  Fig. S9 ). Coculture of c-kit cells with SOD1 -G93A astrocytes for 48 h reduced the percentage of ROS-producing cells in comparison with vehicle treatment (P , 0.00001) and coculture with mSOD1 cells (P , 0.00001). Only a small reduction in ROS was observed when using GLT1 -kd-c-kit cells; this reduction was significantly less than in the wt cells (P , 0.00001). These findings suggest that c-kit exposure exerts an antioxidant effect that is linked to GLT1 expression and is abolished by the presence of mSOD1. The presence of GLT1 on the cell membrane of c-kit cells and the reduction of ROS, which might be beneficial by preserving GLT1 function, is in keeping with the neuroprotective effect that has been observed in wt c-kit cells and not in mutant c-kit or GLT1 -kd-c-kit cells.
DISCUSSION
The major finding of the present study is that systemic injection of c-kit + stem/precursor cells in a mouse ALS model results in consistent engraftment of cells and is associated with an amelioration of the disease phenotype, supporting the feasibility and efficacy of this type of somatic cell transplantation as a promising therapeutic strategy for ALS. Cellular transplantation is receiving growing interest as a means of replacing lost neurons with exogenously supplied cells and as a means of neuroprotection. However, previous studies also support the role of non-neuronal cells in the pathogenesis of ALS and suggest that increased proportions of healthy wt nonneuronal cells are related to the prolongation of animal survival times (14) . These data further sustain the hypothesis that non-neuronal cell transplantation is a possible therapeutic approach to ALS treatment. Experimental approaches of bone marrow cell transplantation (16, 17) , as well as astrocyte replacement based on focal transplantation, exert a positive effect on motor neuron disease in animal models (31) . Among the potential sources of cells that can be used, our population of c-kit + stem/precursor cells features attractive characteristics, including the ease and ethics of procurement (since they can be derived from autologous or donor bone marrow cells), growth potential in vitro and migration capacity from the blood circulation to the spinal cord parenchyma (allowing non-invasive transplantation without complete bone marrow replacement). Indeed, these cells exhibited robust survival in the CNS and did not cause any side effects such as tumor formation. Furthermore, we demonstrated that the transplanted cells localize throughout the entire spinal cord and in the specific areas that are compromised by ALS: the cervical/lumbar enlargement, the anterior horns and the areas around endogenous motor neurons. Neuronal death that occurs in the ALS spinal cord could be a signal that promotes c-kit + cell migration from the blood. Engrafted c-kit + cells maintain their in vitro phenotype: they are round or fusiform small cells that are positive for c-kit and EAAT2 and do not acquire unexpected neuroectodermal phenotypes or fuse with endogenous cells. The bone marrow contains multiple distinct stem and progenitor populations, including hematopoietic stem cells, mesenchymal stem cells and vascular precursors. The c-kit receptor tyrosine kinase was originally detected in a class of murine hematopoietic stem cells with long-term reconstituting ability in irradiated recipients (25) . c-kit is expressed on ES cells and cell populations found at the early embryoid stages of development. It is produced during the hemangioblast stage and is subsequently coexpressed with Flk1, marking the establishment of hematopoiesis (29) . c-kit has been found in several populations of stem cells in the adult liver, brain, pancreas, and heart (30). c-kit-transplanted SOD1 mice showed an amelioration of the motor neuron phenotype, as demonstrated by neuromuscular function tests, delayed disease onset and progression and increased survival. Treatment with c-kit + cells significantly prolonged survival by 11.88% compared with the vehicle-treated group. These observations agreed with the neuropathological analysis, which revealed a significant reduction in motor neuron and axon loss at 110 days of age when compared with the vehicle treatment. Furthermore, we demonstrated that the transplantation of c-kit + cells improves the survival of SOD1 mice significantly more than that of fibroblast grafts, supporting the hypothesis of a specific therapeutic effect for were present. For comparison, it has been quantified that in physiological conditions the mean total number of neurons above the dimension of 10 000 mm 3 (corresponding to motor neurons) in lamina IX of the control mice is about 13 000 cells (40) . The majority of c-kit
+ engrafted cells are located ventrally to a line drawn through the central canal, perpendicular to the ventral spinal cord sulcus. This area includes both the anterior horn and the intermediate zone. Neuronal degeneration has been observed in ALS patients and SOD1 mice not only in the ventral horn, but also in the intermediate zone (24, 41) . Overall, our data support that donor c-kit + cells are in sufficient number to exert positive effects to counteract neurodegenerative processes. Interestingly, c-kit + cells express GLT1, while fibroblasts and bone marrow express little or no GLT1. The glutamate transporters GLT1 and GLAST are widely expressed in astrocytes in the brain where they play an important role in regulating glutamatergic neurotransmission. However, both GLT1 and GLAST are also expressed in peripheral tissues. GLT1 is expressed in several tissues, such as glandular, but also by perivenous hepatocytes and follicular dendritic cells in the spleen, lymph nodes and bones. The glutamate transporters in the periphery probably play functions apart from glutamatergic neurotransmission (42) .
The increased survival time we observed with c-kit + cells, though limited, is relevant considering previously reported results of focal astrocyte transplantation (31) and our previous results with bone marrow cell transplantation, both of which extended survival by 10%. The benefits of c-kit transplantation have been previously described, primarily in the context of ischemic cardiomyopathy (30) . Here, we showed the ability of c-kit + cell transplantation to exert a neuroprotective effect on degenerating motor neurons. One possible mechanism is the preservation of GLT1 levels after c-kit transplantation in the spinal cord. In both human and animal models of ALS, numerous studies suggest that dysfunctional astrocytic glutamate transport, specifically that by GLT1 (hEAAT2), may play a key role in disease progression, inducing excitotoxic motor neuron death (12) . In line with our data, it has been previously described that replacement of altered astroglial EAAT2 function may be of therapeutic benefit (31) . However, the transplantation of astrocyte precursors with or without genetic modification requires a direct intraparenchymal injection that is more invasive than the systemic injection that we used in this work. We observed a reduction in levels of activated microglia after cell transplantation, suggesting a potential anti-inflammatory effect of c-kit + cells. Since a lower level of mutant SOD1 in microglia affects disease duration after onset, the increased disease duration that we observed may have been associated with microglial modulation by c-kit + cells. In addition to GLT1 preservation, we observed an increase in the production of the vascular factors VEGF and angiopoietin-2, which can exert a direct neuroprotective effect on endogenous cells. We hypothesized that the therapeutic effect of c-kit relies on multiple mechanisms that include both the GLT1 expression as well as VEGF and Ang 2 production. In fact, mSOD1 cells that do not provide the same benefit to the phenotype of ALS mice produced less VEGF and Ang 2 than wt cells. However, we did not demonstrate any direct effect on BBB integrity. The modification of BBB integrity has been described previously in SOD1-ALS models (37), but we did not perform a deeper investigation of this point. In vitro experiments demonstrate the ability of c-kit + cells to protect motor neurons from excitotoxicity as well as to limit the oxidation of mutant astrocytes. We observed that the expression of mutant SOD1 protein in c-kit cells drastically reduced their therapeutic effect in vivo after cell transplantation, and in vitro in coculture assays. These results are in agreement with previous observations by us and others. In bone marrow transplantation experiments, an ALS mice model transplanted with mSOD1 cells showed shorter survival and disease progression than those transplanted with bone marrow from wt mice (16, 17, 43) . Focal transplantation of glial restricted precursor cells (GRPs) into the spinal cord demonstrated that only mSOD1 -GRPs, not wt, caused significant time-dependent motor neuron loss, induced ubiquitin-positive inclusions in surviving motor neurons and increased microgliosis in ventral gray matter. In addition, mSOD1 GRPs produced a mild decline in forelimb strength, demonstrating that GRP-derived astrocytes focally influence motor neuron loss (44) . The mechanisms by which SOD1 mutant cells influence the disease course are not completely understood and are mainly attributed to an unknown gain of toxicity of the mutant enzyme and mitochondrial dysfunction (1) . It has been demonstrated that mSOD1 microglia have different characteristics and respond in a way different than wt cells (39) . Regarding these peculiar mSOD1-microglia features, it has been suggested that intracellular and extracellular mSOD1 proteins, acting on different pathways, may increase the production and release of ROS and augment the inflammatory cytokine cascade. Furthermore, these ROS and cytokines may increase the susceptibility of motor neurons to glutamate toxicity and inhibit the function and expression of astrocytic glutamate transporters, leading to further neurotoxicity (39) . Similar mechanisms might play a role in our set of experiments with c-kit + cells. In fact, in the coculture experiments with mSOD1 astrocytes and c-kit + cells, the ROS production was higher with respect to the wt c-kit + cells. Further, in vitro mSOD1 c-kit cells did not protect SOD1 -G93A motor neurons from extracellular glutamate neurotoxicity like the wt cells did. Indeed, the GLT1 activity of SOD1 astrocytes was reduced in the presence of m-c-kit SOD1 cells compared with wt cells. The mechanisms underlying the differences between wt and mutant c-kit + cells are not completely understood and that further studies are need to address this issue and to evaluate a possible systemic effect of these cells outside the CNS. In the present set of experiments, we do not specifically address whether the efficiency to enrich c-kit + cells and their neuroprotective effects depend on the age of the bone marrow of donor mice. However, it has been reported that the CD34(2/low)c-Kit(+)Sca-1(+)lineage marker(2) (CD34(2)KSL) cells, a highly enriched hematopoietic stem cell population, significantly reduced their repopulating ability with aging (45). Thus, it is possible that the age of donor mice influences the properties of c-kit + cells. Some cell transplantation strategies are based on an increased production of trophic factors, with or without genetic cell modification. This approach shows promise in ALS models (46) . The c-kit + cell population that we used
presents some advantages, including the endogenous production of neuroprotective factors and the ability to migrate from the bloodstream to the CNS, properties that make this cell type a potential candidate source for an ex vivo gene therapy approach employing growth factors. In terms of other cell transplantation experiments in motor neuron disease models (31), we demonstrated that the beneficial effects observed after stem cell transplantation arise from multiple events involving the transplanted cells.
Our results provide what we believe to be the proof of principle that the transplantation of c-kit + stem/precursor cells could have a beneficial role in the course of ALS and may constitute a potentially viable approach to ALS therapy.
MATERIALS AND METHODS
Animal models
We used transgenic mice of the strain B6.Cg-Tg(SOD1-G93A)1Gur/J, which carries a high copy number of the mutant human SOD1 allele containing the Gly93Ala (G93A) substitution. Progeny for experimental analysis were obtained by breeding SOD1 -G93A transgenic with C57BL/6 wt mice. Transgenic mice were identified by polymerase chain reaction as described previously (8) .
Transgenic Ten(ACTbEGFP)1Osb mice expressing enhanced GFP under the control of a chicken b-actin promoter and cytomegalovirus enhancer were used as donors. The transgene is widely expressed in all tissues except for erythrocytes and hair (47) . All transgenic animals were purchased from The Jackson Laboratory. All animal experiments were approved by University of Milan and Italian Ministry of Health review boards, in compliance with NIH guidelines (48) .
Cell culture and characterization
Cells were isolated from the bone marrow of wt and GFP mice. Bone marrow lineage-positive cells were depleted by immunomagnetic separation magnetic-activated cell sorting (MACS) with the Lineage Cell Depletion Kit (Miltenyi Biotec). Cells were plated in Dulbecco's modified eagle medium (DMEM) (Invitrogen) containing 15% fetal calf serum (FCS) (Invitrogen), 10 ng ml 21 epidermal growth factor (Sigma-Aldrich), fibroblast growth factors (Sigma-Aldrich), platelet-derived growth factor BB (R&D Systems) and leukemia inhibitor factor (Chemicon International). After 4 weeks, c-kit cells were immunomagnetically selected using CD117 MicroBeads (Miltenyi Biotec).
Flow cytometry analysis
Isolated c-kit cells expanded in vitro were analyzed by FACS to determine the cell surface phenotype. Samples were stained with fluorochrome-conjugated antibodies against these proteins: CD34, CD45 (30-F11), Lin + markers (Milteniy), Sca-1 (E13-161.7), CD31 (MEC13.3), CD44 (IM7), CD105 (MJ7/18), Thy1.1 (OX-7), CD15 (MMA), CD133 (eBioscience), CD13 (R3-242) and c-kit (ack45 and 2B8). Isotype-matched mouse immunoglobulin served as control. All antibodies were from BD Biosciences unless otherwise indicated. Flow cytometric analysis was conducted using an FACS Vantage SE (BD).
Immunocytochemistry on cultured cells
Cultured cells were fixed in 4% para formaldehyde (PFA) (10 min) at room temperature. After rinses with phosphatebuffered saline (PBS) and preincubation in a mixture of 5% normal serum and 0.25% Triton X-100 in PBS, cultures were incubated with the following primary antibodies (see below) overnight at 48C: c-kit (rat, 1:100, BD), desmin (mouse monoclonal, 1:100, Novocastra), a-smooth muscle actin (mouse monoclonal, 1:100, Sigma), Oct4 (rabbit, 1:100, Chemicon Millipore), GLT1 (rabbit, 1:100, Sigma) and Alexa Fluor 488 anti-GFP antibodies (rabbit polyclonal, 1:400; Molecular Probes, Invitrogen). After repeated rinses in PBS, the primary unconjugated antibodies were incubated with fluorescein isothiocyanate (FITC) and R-phycoerythrin (RPE) or TRITC-conjugated secondary antibodies (1:100; DAKO) ( 
Western blot analysis
Cells were collected in lysis buffer (0.05 M Tris/HCl, 9.5% glycerol, 2% sodium dodecyl sulfate, 0.004% bromophenol blue, 1.6% beta mercaptoethanol and a cocktail of protease inhibitors from Sigma-Aldrich). Each sample was sonicated 2 × 10 s at 40 W, boiled for 4 min and then centrifuged at 13 000g for 10 min. The supernatant was collected and proteins were quantified using the Lowry method. Twenty micrograms of protein extract was separated on a 9% sodium dodecyl sulphate -polyacrylamide gel electrophoresis (SDS -PAGE) and transferred to nitrocellulose membranes (PROTRAN, Whatman GmbH) for antibody staining. The following antibodies were used: Oct-4 (rabbit, Chemicon Millipore, diluted 1/1000), Sox2 (rabbit, Chemicon Millipore, diluted 1/1000), klf4 (rabbit, Abcam, diluted 1/500) and c-myc (rabbit Abcam, diluted 1/100). The membranes were incubated with a secondary peroxidase-conjugated anti-rabbit antibody (Dako, diluted 1/2700) and signals were detected with an ECL detection kit (Amersham, GE Healthcare).
GLT1-kd by transfection of shRNA GLT1 was kd in c-kit cells by transfection with plasmids containing shRNA constructs targeting the GLT1 coding sequence.
Five different target constructs were tested. Mission plasmids were purchased from Sigma along with the scramble control sequences. Transduction and selection of clones was done following the manufacturer's instructions. C-kit cells transduced with control construct (control shRNA) and c-kit cells with shRNA to knock down GLT1 (GLT1 -kd-c-kit cells) were analyzed by immunocytochemistry and western blot to determine the protein expression profile.
Cell transplantation
Seventy-day-old transgenic SOD1 -G93A mice were transplanted with c-kit + cells (1 × 10 6 cells), vehicle only (saline solution) or primary murine fibroblasts (1 × 10 6 cells) by injection through the tail vein. Cultured murine dermal fibroblasts (primary culture from neonatal skin) were used as controls, as described previously (49) . We also transplanted c-kit + cells from SOD1G93A mice, as well as GLT1 -kd-c-kit cells. We prepared c-kit + cells from SOD1G93A mice as previously described for the wt. These cells were also genetically engineered to express green fluorescent protein (GFP) driven by a cytomegalovirus promoter in a G418 selectable fashion. The cells were harvested and prepared for transplantation as described previously (48) .
Each group of SOD1 -G93A mice included 24 mice (12 males, 12 females), which were evaluated up to the end stage for rotarod, survival record and histological evaluation of donor cell phenotype. The study was designed so that littermates were distributed equally among the transplanted and untransplanted groups.
Three groups of animals (each composed of six mice per time point per condition) were sacrificed at 110 days of age for histological analysis, quantification of motor neurons and axons, growth factor evaluation via ELISA and western blot analysis.
Tissue analysis
Animals were sacrificed, perfused and fixed with 4% PFA in PBS (pH 7.4). The spinal cord was isolated, immersed in PFA solution for 1 h and then soaked in a 20% sucrose in PBS solution (pH 7.4) overnight and frozen in Tissue Tek OCT compound (Sakura) with liquid nitrogen. The tissues were cryosectioned and mounted on gelatinized glass slides. Every tenth 20 mm section was collected. All sections were blocked with 1% FCS in PBS and permeabilized with 0.25% Triton X-100. Sections were processed for multiple markers to determine the cellular phenotype of GFP-labeled cells. and MAC-2 (activated microglia, rat anti-mouse 1:100, Cedarlane). For characterization of the hematopoietic phenotype, we used antibodies raised against CD45 (rat, BD, 1:100), CD11b (rat, BD 1:100) and CD14 (rat, BD, 1:100); for the endothelial phenotype we used antibodies raised against CD31 (rat BD, 1:50), VEGFR-2 + (rabbit, Acris Antibodies GmbH, 1:100), von Willebrand factor (VWF) (rabbit, Thermo Scientific 1:100); for pericyte phenotype we used antibodies raised against desmin (mouse monoclonal, Novocastra 1:100) and a-smooth muscle actin (mouse monoclonal, Sigma 1:100). For c-kit immunostaining we used rat anti-CD117 (BD, 1:100). Proliferating cells were identified with Ki67 (1:400; monoclonal; Lab Vision Corp). Host cells of the transgenic SOD1G93A spinal cord were identified with an antibody targeting human SOD1 (1:2,000; polyclonal; Chemicon). Presynaptic terminals were identified with an antibody targeting synapsin (1:100; polyclonal; BD Biosciences).
For ubiquitin expression, spinal cords were stained for ubiquitin (1:200; mouse Abcam), and aggregation was visualized in transplanted cells via double-staining with GFP. Donkey, goat, mouse, rabbit, or rat antibodies conjugated with FITC, RPE, CY3 or biotin (1:200; Jackson ImmunoResearch Laboratories, Inc. and Dako) were used for 1 h at room temperature as secondary antibodies when unconjugated primary antibodies were used. Anti-GFP antibody rabbit serum Alexa 488 (1:400 dilution; Molecular Probes) was used to reveal GFP expression.
Coexpression of GFP and tissue-specific markers was evaluated by conventional fluorescence microscopy (Zeiss Axiophot) and by laser confocal scanning (Leica TCS SP2 AOBS) microscopy. Optical dissectors and random sampling were used to obtain an unbiased stereological estimate of the number of GFP-positive cells. To quantify donor cells, a systematic random series of every tenth coronal section (20 mm) throughout the entire spinal cord was obtained (a mean of 25 sections per animal). The numerical density of cells was then estimated using the optical dissector method (50, 51) . Optical dissectors sized 100 × 70 × 14 mm were randomly sampled, and the number of positive cells in each dissector was quantified. The density was calculated by dividing the total number of donor cells by the total volume of optical dissectors. The total volume of tissue per specimen (Vcord) containing donor cells was calculated using the Cavalieri method. This total volume of tissue, multiplied by the number of donor cells per cubicmicrometer (Nv), yielded the total number of donor cells per specimen (n ¼ Nv × Vcord) (50, 51) .
The proportion of transplanted cells and actively proliferating cells (Ki67) was then expressed as a percentage of the total number of transplanted cells counted per animal.
Assessment of motor function and survival
Vehicle-and cell-injected SOD1 -G93A mice were monitored daily following transplantation for clinical signs of disease onset. Beginning the week before transplantation, the motor performance of all mice was assessed weekly using an accelerating rotarod device (4 -40 rpm Rota-Rod 7650; Ugo Basile, Comerio, Italy). The length of time that mice remained on the rotarod was recorded. Each mouse performed three consecutive trials and the longest latency to fall was recorded. The investigators performing the behavioral assessment were blind to the treatment. The rotarod test was analyzed using analysis of variance (ANOVA) followed by a Tukey post hoc analysis for multiple comparison.
Disease stages were determined as follows (14) : disease onset was defined retrospectively as the time when mice reached peak body weight. The early symptomatic stage was defined as 10% weight loss from maximal weight (the result of denervation-induced muscle atrophy).
Mortality was scored as the age at which the mouse was unable to right itself within 30 s when placed on its back as described previously (52) . The Kaplan-Meier survival analysis and log-rank test were used for survival comparisons.
Motor neuron and axon count
Paraffin serial sections (12.5 mm) of lumbar spinal cord were processed for Nissl-staining quantification of motor neuron numbers via light microscopy as described previously (53) . For axon count, the tissue was dissected, immersed in 2.5% glutaraldehyde overnight and post-fixed in 2% osmium tetroxide. Samples were then dehydrated in ethanol and embedded in Epon. Semi-thin transverse sections (1 mm) were stained with toluidine blue. L4 roots were examined for axon counting on the optic microscope.
GLT1 immunohistochemistry and western blot analysis
The expression of GLT1 protein in c-kit + /GFP + cells engrafted in the spinal cord was determined using immunohistochemistry as described above with GLT1 antibody (carboxyl terminus-directed antibody; 1:500; polyclonal) (54) . Homogenized spinal cord samples were derived from the wt, vehicle-, fibroblast-and c-kit-transplanted mice. Twenty micrograms of proteins were separately subjected to SDS -PAGE (10%). Blots were probed with antibody specific for GLT1 (1:5000) (31). Immunoreactivity was visualized by enhanced chemiluminescence and then quantified densitometrically using ImageJ software.
Enzyme-linked immunosorbent assay
For in vitro analysis after 60 h of incubation, the supernatants of wt and mutant SOD1 c-kit, fibroblast and control media (n ¼ 6 for each group) were collected and frozen. Transplanted animals and relative controls (n ¼ 6 for each group) were sacrificed at 110 days, and fresh-frozen samples of whole lumbar spinal cord were obtained to determine the levels of candidate trophic factors. Murine VEGF was measured in duplicate by ELISA (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. Ang 2 detection by ELISA was performed as previously described (55, 56) , using anti-mouse Ang 2 antibody (Millipore). Recombinant murine Ang 2 (Millipore) served as standard.
Western blot of spinal cord for tight-junction proteins
We isolated spinal cord from wt, vehicle-, fibroblast-and c-kit-treated SOD1G93A mice at 110 days (n ¼ 6). We conducted three independent experiments. Twenty micrograms of proteins was used for analysis by 10% SDS -PAGE and subsequently transferred to a nitrocellulose membrane. This membrane was then blocked for 1 h with 5% non-fat milk in Tris-buffered saline. The membrane was washed and incubated with a horseradish peroxidase-conjugated secondary antibody for 1 h. Reactivity was detected using an enhanced chemiluminescence detection system (Amersham, Piscataway, NJ, USA).
We used the following primary antibodies: goat polyclonal anti-actin (1:1000, Santa Cruz Biotechnology, Santa Cruz, CA, USA), goat polyclonal anti-ZO-1 (1:250, Santa Cruz Biotechnology) and mouse monoclonal anti-occludin (1:50, BD Biosciences, San Jose, CA, USA). The density of bands for ZO-1 and occludin was quantified using scanning densitometry relative to b-actin signal (ImageJ software). Signal was within the linear range for each protein studied.
Iba1 immunohistochemistry
Microglial reactivities were assessed by immunohistochemical staining with Iba1 antibody (Wako; 1:200; polyclonal). Fluorescence intensity was evaluated in ventral gray matter using ImageJ software.
Motor neuron toxicity
Neuroprotection in spinal cord organotypic cultures derived from postnatal day 8-9 wt mice was carried out as described previously (38) . Motor neurons were cultured for 5-7 days before the addition of c-kit + cells (wt, GLT1-kd or mSOD1) (1 × 10 5 cells). After an additional 7 days, 100 mM THA or 100 mM DL-threo-b-benzyloxyaspartate (TBOA) (Tocris) were administered. Surviving motor neurons were quantified 2-3 weeks later by staining for phosphorylated neurofilaments (SMI-32).
Extracellular glutamate analysis and detection of ROS production
We prepared glial monolayers from spinal cords of transgenic SODG93A and SODWT newborn pups and their nontransgenic littermates as described previously (56, 57) . We performed coculture of astrocytes with wt -c-kit cells (wt or GLT1-kd-c-kit) (1 × 10 5 cells) (22) . The concentration of glutamate in the cell-free supernatant was measured by an enzymatic assay as described previously (58) . Glial cells absorbed exogenously added glutamate in a time-dependent manner (0.5 or 1 mM). Cultured medium was collected for glutamate analysis 24 h after treatment (58) .
Detection of total cellular ROS was performed using the Image-iT LIVE Green Reactive Oxygen Species Detection Kit according to the manufacturer's instructions (Molecular Probes, Invitrogen). This assay is based on the principle that the live cell-permeable compound carboxy-H2DCFDA emits a bright green fluorescence when it is oxidized in the presence of ROS. Quantification of ROS production was performed in two ways: (i) counting the number of fluorescent cells and (ii) measuring the intensity of the fluorescence emitted by the cells. The relative fluorescence intensity was measured in randomly selected fields for each treatment and was analyzed and quantified using ImageJ software.
